Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low INR to Minimize bleeding with mechanical valves Trial (LIMIT)
2023-508532-56-00Phase 3Authorised
- Sponsor
- Hamilton Health Sciences
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised trial of warfarin, phenprocoumon and acenocoumarol in Mechanical valve replacement (2 arms), sponsored by Hamilton Health Sciences. Primary endpoint: Thrombosis/thromboembolism and major bleeding (composite primary endpoint). Planned start Nov 2023; status: authorised.
02
Drugs
warfarinphenprocoumonacenocoumarol
03
Conditions
Mechanical valve replacement
Beyond the preview
Go deeper on 2023-508532-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508532-56-00.